Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3323 ARTÍCULOS , VIENDO DEL 2341 AL 2355

Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence

Bortolato M, Shih JC.

Int Rev Neurobiol. 2011;100:13-42. doi: 10.1016/B978-0-12-386467-3.00002-9.

The pharmacology of selegiline

Magyar K.

Int Rev Neurobiol. 2011;100:65-84. doi: 10.1016/B978-0-12-386467-3.00004-2.

Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection

Naoi M, Maruyama W, Inaba-Hasegawa K, Akao Y.

Int Rev Neurobiol. 2011;100:85-106. doi: 10.1016/B978-0-12-386467-3.00005-4.

Multimodal drugs and their future for Alzheimer's and Parkinson's disease

Van der Schyf CJ, Geldenhuys WJ.

Int Rev Neurobiol. 2011;100:107-25. doi: 10.1016/B978-0-12-386467-3.00006-6.

Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease

Weinreb O, Amit T, Riederer P, Youdim MB, Mandel SA.

Int Rev Neurobiol. 2011;100:127-49. doi: 10.1016/B978-0-12-386467-3.00007-8.

Rasagiline in Parkinson's disease

Chahine LM, Stern MB.

Int Rev Neurobiol. 2011;100:151-68. doi: 10.1016/B978-0-12-386467-3.00008-X.

Selective inhibitors of monoamine oxidase type B and the "cheese effect"

Finberg JP, Gillman K.

Int Rev Neurobiol. 2011;100:169-90. doi: 10.1016/B978-0-12-386467-3.00009-1.

Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease

Unzeta M, Sanz E.

Int Rev Neurobiol. 2011;100:217-36. doi: 10.1016/B978-0-12-386467-3.00011-X.

Executive functions in Parkinson's disease: systematic review and meta-analysis

Kudlicka A, Clare L, Hindle JV.

Mov Disord. 2011 Nov;26(13):2305-15. doi: 10.1002/mds.23868. Epub 2011 Oct 3.

N-(4-(4-(2-(2-[(18)F]Fluoroethoxy)phenyl)piperazine-1-yl)butyl)-4-(3-thienyl)benzamide

Leung K.

2011 Jun 24 [updated 2011 Oct 6]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013.

Exercise and Parkinson's disease

Playford ED.

J Neurol Neurosurg Psychiatry. 2011 Nov;82(11):1185. doi: 10.1136/jnnp-2011-300987.

Evaluation of striatal oxidative stress in patients with Parkinson's disease using [62Cu]ATSM PET

Ikawa M, Okazawa H, Kudo T, Kuriyama M, Fujibayashi Y, Yoneda M.

Nucl Med Biol. 2011 Oct;38(7):945-51. doi: 10.1016/j.nucmedbio.2011.02.016. Epub 2011 Apr 21.

Biomarkers of Parkinson's disease and Dementia with Lewy bodies

Henchcliffe C, Dodel R, Beal MF.

Prog Neurobiol. 2011 Dec;95(4):601-13. doi: 10.1016/j.pneurobio.2011.09.002. Epub 2011 Sep 19.

Successful percutaneous epicardial ablation of an accessory pathway located at the right atrial appendage

Köse S, Başarıcı I, Kabul KH, Barçın C.

Turk Kardiyol Dern Ars. 2011 Oct;39(7):579-83. doi: 10.5543/tkda.2011.01551.

Analysis of Parkinson's disease and subsequent cancer risk in Taiwan: a nationwide population-based cohort study

Sun LM, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH.

Neuroepidemiology. 2011;37(2):114-9. doi: 10.1159/000331489. Epub 2011 Oct 7.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias